Q2 FY2026 · ended Jun 30, 2026 · Revenue $35.00M · Filed Aug 7, 2026
Actinium Pharmaceuticals, Inc. (ATNM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $35.0 million and net income of $27.9 million. Free cash flow was -$5.7 million. As of Jun 30, 2026 it held $36.5 million in cash and investments and $1.3 million in total debt.
Revenue
$35.00M
Net income
$27.90M
+505.7% vs year-ago quarter
Operating cash flow
$-5.18M
+4.0% vs year-ago quarter
Free cash flow
$-5.66M
+3.7% vs prior quarter
EPS
$0.89
+504.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
31.44M
+0.8% vs year-ago quarter
Net cash
$35.13M
Q2 FY2026
Operating margin
78.8%
Q2 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ATNM (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1388320
- Former names
- Cactus Ventures, Inc. (until Mar 29, 2013)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $35.0M | — | $0 | $90,000 | — |
| Operating income | $27.6M | -$5.9M | -$6.4M | -$5.7M | -$7.5M |
| Net income | $27.9M | -$5.5M | -$5.9M | -$5.1M | -$6.9M |
| Diluted EPS | $0.89 | -$0.18 | -$0.19 | -$0.16 | -$0.22 |
| Operating cash flow | -$5.2M | -$5.9M | -$5.3M | -$6.3M | -$5.4M |
| Free cash flow | -$5.7M | -$5.9M | -$5.4M | — | — |
| Total assets | $40.2M | $45.4M | $51.8M | $56.2M | $63.0M |
| Total liabilities | $9.9M | $43.1M | $43.9M | $42.4M | $44.0M |
| Stockholders' equity | $30.3M | $2.3M | $7.8M | $13.8M | $19.0M |
| Cash and investments | $36.5M | $42.1M | $48.0M | $53.4M | $59.9M |
| Total debt | $1.3M | $1.5M | $1.7M | $1.1M | $1.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Oct 15, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 15, 2026 | Oct 14, 2026 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
Aug 14, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Other events
|
Jun 18, 2026 | Jun 18, 2026 |
| 8-K |
Current report
Listing notice, Regulation FD disclosure
|
May 29, 2026 | May 27, 2026 |
All 511 Actinium Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.